Aclarion director William Wesemann buys $5,031 in company stock By Investing.com

Aclarion, Inc. () director William Wesemann recently purchased shares of the company’s common stock. The transaction, detailed in a Form 4 filing, occurred on August 13, 2026.

Mr. Wesemann acquired 2,150 shares of Aclarion common stock on the public market at a price of $2.34 per share, resulting in a total value of $5,031. Following this acquisition, Mr. Wesemann directly holds 23,713 shares of Aclarion common stock.The insider purchase comes as ACON trades at $2.46, down 46.5% year-to-date and near its 52-week low of $1.95. The company, with a market cap of $7.1 million, holds more cash than debt on its balance sheet and maintains a strong current ratio of 16.2, though it remains unprofitable over the last twelve months. According to InvestingPro analysis, the stock appears undervalued at current levels. For deeper insights into ACON’s financial health and access to 8 additional ProTips, visit InvestingPro.

In other recent news, Aclarion Inc. announced several significant developments. The company rejected a $4 per share takeover bid from Echo Lake Capital, with the board stating that the offer undervalues Aclarion and disproportionately favors the bidder. In a strategic move to enhance market access, Aclarion partnered with PRIA Healthcare to support the reimbursement process for its Nociscan platform, aiming to expand patient access and commercial adoption. Additionally, the Texas Spine Care Center has joined Aclarion’s CLARITY trial, which evaluates the Nociscan diagnostic platform for chronic low back pain.

Aclarion also entered into an agreement with the Institute of Neuro Innovation in Los Angeles to study the integration of Nociscan’s chemical biomarker data with SPECT-CT imaging for treating chronic low back pain. Furthermore, the Nociscan technology was used in a research study examining biological factors associated with back pain, conducted by institutions including the University of Zurich and UCSF. This study received the 2026 ISSLS Best Paper Award, highlighting the potential of Nociscan’s methodology in medical research. These recent developments underscore Aclarion’s active role in advancing research and technology in the field of chronic pain management.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.